Secondary acute myeloid leukemia (AML) is a blood cancer that arises from other blood disorders or previous cancer treatment. Those with secondary AML tend to have a less favorable outlook than ...

For children with acute lymphoblastic leukemia (ALL), measurable residual disease (MRD) after the end of first consolidation (EOC) can be used to predict the need for subsequent MRD measurements ...

Researchers from the Tumor Profiler consortium have combined single-cell multi-omics and functional profiling for 21 AML ...

The technology accurately detects the presence of these gene fusions in acute promyelocytic leukemia ... Radon, Even at Levels Below EPA Guideline for Mitigation, Is Linked to Childhood Leukemia ...

The trial aims to assess Luvelta's efficacy and safety, with most of its sites due to open by the end of the year.

Rigorous surveillance of children at high risk for developing myelodysplastic syndrome (MDS) is especially warranted, ...

Jylamvo is an oral liquid formulation of methotrexate originally approved in 2022 for adults with acute lymphoblastic ...

A new study reveals a modular CAR-T approach that effectively targets heterogeneous antigens in paediatric acute myeloid leukaemia, enhancing treatment success through combinatorial targeting.

Researchers sought to determine whether DNA methylation markers could be helpful in risk stratification for patients with AML and normal cytogenetics.

Obecabtagene autoleucel (obe-cel; Aucatzyl) has been approved by the FDA to treat patients with relapsed or refractory B-cell ...

Treatment with Scemblix was shown to improve response rates in patients with newly diagnosed Philadelphia chromosome-positive ...